Gut Microbiome in Gynecological Cancer Patients With Pelvic Toxicity: Controls Versus Ozone Treatment. (MicrOzoGineTox)

N/ANot Yet RecruitingNCT07259681

Bernardino Clavo, MD, PhD38 enrolled

Overview

Patients treated for gynecological tumors with radiotherapy (RT) and/or chemotherapy (CT) frequently develop pelvic toxicity (TPIRQT), a condition that can become persistent, progressive, and refractory to standard treatments. This toxicity, affecting the rectum (proctitis), bladder (cystitis), and vagina (mucositis), severely deteriorates quality of life. Standard options for refractory cases are limited; at our center, rectal ozone therapy is used with high rates of symptomatic improvement (66-75%). Emerging evidence suggests a link between gut microbiota and the development of TPIRQT. However, it is unknown how rectal ozone therapy may influence the gut microbiome or if this modulation is part of its therapeutic mechanism. This prospective observational study will investigate the potential relationship between gut microbiome profiles (composition and diversity), the presence and severity of TPIRQT, and the response to rectal ozone therapy.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Pelvic Toxicity Radiation Toxicity

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria for all patients (Cases and Controls): 1. Adult women (\>=18 years). 2. Diagnosed with gynecological tumors (any location and stage). 3. Previously treated with radiotherapy and/or chemotherapy. 4. Must accept and sign the specific informed consent for this study. Additional Inclusion Criteria for inclusion in the TPIRQT Group (Cases): 5. Must present chronic TPIRQT with \>= 3 months of duration after habitual symptomatic treatment. 6. Must have a toxicity Grade of 2 (moderate symptoms, limiting instrumental ADL) or higher, according to the CTCAE v.5.0 scale. Exclusion Criteria for all patients (Cases and Controls): 1. Not meeting all inclusion criteria. 2. Presence of active inflammatory bowel disease (e.g., Crohn's Disease, Ulcerative Colitis) or a history of major gastrointestinal resection (excluding appendectomy) that could significantly alter gut anatomy and microbiota. 3. Any uncontrolled intercurrent illness or psychiatric condition that, in the investigator's opinion, would limit compliance with study requirements or interfere with the interpretation of results. 4. Unwillingness or inability to provide written informed consent for study participation.

Outcomes

Primary Outcomes

Comparison of gut microbiome profile (composition and diversity) between TPIRQT and Control groups

Gut microbiome composition and diversity (from a single sample) in control patients will be compared to the baseline profile of patients with TPIRQT.

Time frame: Baseline (single time point for controls, pre-ozone for cases)

Change in gut microbiome profile (composition and diversity) in patients with TPIRQT after rectal ozone therapy.

Gut microbiome composition and diversity will be analyzed from stool samples using 16S ribosomal RNA gene sequencing.

Time frame: Baseline (pre-ozone therapy) , 4 Months (post-ozone therapy)

Correlation of gut microbiome profile with grade of pelvic toxicity.

Toxicity will be assessed using: i) the CTCAE v.5.0 scale from the NCI , and ii) the EORTC QLQ-CX24 questionnaire. This will be evaluated for its relationship to microbiome data.

Time frame: Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).

Secondary Outcomes

Correlation of gut microbiome profile with health-related quality of life (HRQoL).

HRQoL will be assessed using: i) the EQ-5D-5L questionnaire, and ii) the EORTC QLQ-C30 questionnaire. This will be evaluated for its relationship to microbiome data.

Time frame: Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).

Correlation of gut microbiome profile with anxiety and depression levels.

Anxiety and depression will be assessed using the Hospital Anxiety and Depression Scale (HADS). This will be evaluated for its relationship to microbiome data.

Time frame: Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).

Correlation of gut microbiome profile with biochemical markers of oxidative stress and inflammation.

Serum samples will be collected to analyze biochemical parameters of oxidative stress and inflammation and their potential relationship with gut microbiome composition.

Time frame: Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).

Gut Microbiome in Gynecological Cancer Patients With Pelvic Toxicity: Controls Versus Ozone Treatment. (MicrOzoGineTox)

Overview

Conditions

Eligibility

Locations (2)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts